Recent pre-clinical studies indicated that vertical blockade of the PI3K/AKT/mTOR pathway, i.e., combination of agents targeting more than one molecule in a signaling pathway, can produce synergistic anti-cancer efficacy with acceptable toxicity [39], [40]. This evidence concerns the gene MTOR and cancer.